125 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s … privacy and security laws and regulations, including, without limitation, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679
424B5
SEEL
Seelos Therapeutics Inc
20 May 24
Prospectus supplement for primary offering
4:16pm
”) for OPMD and SCA3 has been secured in the United States and in the European Union (“EU”). In February 2019, we assumed a collaborative agreement, turned … and in the European Union (“EU”). In February 2019, we assumed a collaborative agreement, turned subsequently into a research grant, with Team Sanfilippo
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
, Orphan Drug Designation (“ODD”) for OPMD and SCA3 has been secured in the United States and in the European Union (“EU”). In February 2019, we assumed
8-K
EX-10.1
faxjkos2
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
pmlw5n noi1ywasiulv2
30 Jan 24
Prospectus supplement for primary offering
6:05am
424B5
huo1oqnxfemebn2zd
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
fztznv
28 Nov 23
Prospectus supplement for primary offering
4:06pm
424B3
ueg3a3qvohgl2wj2afr8
29 Sep 23
Prospectus supplement
4:56pm
8-K
EX-10.1
lrgv jmbd
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
r98yytuq
25 Sep 23
Prospectus supplement for primary offering
6:02am